[go: up one dir, main page]

GB1525181A - Form of flunisolide and the use of flunisolide to treat respiratory diseases - Google Patents

Form of flunisolide and the use of flunisolide to treat respiratory diseases

Info

Publication number
GB1525181A
GB1525181A GB21936/76A GB2193676A GB1525181A GB 1525181 A GB1525181 A GB 1525181A GB 21936/76 A GB21936/76 A GB 21936/76A GB 2193676 A GB2193676 A GB 2193676A GB 1525181 A GB1525181 A GB 1525181A
Authority
GB
United Kingdom
Prior art keywords
fluorisolide
flunisolide
solvent
respiratory diseases
heading
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB21936/76A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of GB1525181A publication Critical patent/GB1525181A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1525181 Particular crystalline form of fluorisolide SYNTEX (USA) Inc 26 May 1976 [27 May 1975 (2)] 21936/76 Heading C2U [Also in Division A5] A novel crystalline form of 6α - fluoro - 11#,21- dihydroxy - 16α,17α - isopropylidenedioxypregna - 1,4 - diene - 3,20 - dione(fluorisolide) having a characteristic X-ray diffraction pattern is prepared by contacting a polymorphic form of fluorisolide with an aprotic non-polar liquid, particularly a liquid halogenated alkane, which is not a solvent for fluorisolide, or by dissolving a polymorphic form of fluorisolide in an aprotic non-polar solvent, particularly a halogenated hydrocarbon solvent, and crystallizing the required product from the solvent. The novel form is particularly stable in the presence of aerosol propellants and aerosols containing it have use in the treatment of respiratory diseases (see Heading ASB, which also includes a further aspect of the invention).
GB21936/76A 1975-05-27 1976-05-26 Form of flunisolide and the use of flunisolide to treat respiratory diseases Expired GB1525181A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58130175A 1975-05-27 1975-05-27
US58130075A 1975-05-27 1975-05-27

Publications (1)

Publication Number Publication Date
GB1525181A true GB1525181A (en) 1978-09-20

Family

ID=27078279

Family Applications (1)

Application Number Title Priority Date Filing Date
GB21936/76A Expired GB1525181A (en) 1975-05-27 1976-05-26 Form of flunisolide and the use of flunisolide to treat respiratory diseases

Country Status (15)

Country Link
JP (1) JPS51144719A (en)
AT (1) AT357702B (en)
AU (1) AU506080B2 (en)
CA (1) CA1075228A (en)
DE (2) DE2661037C2 (en)
ES (1) ES448220A1 (en)
FR (1) FR2361900A1 (en)
GB (1) GB1525181A (en)
HK (1) HK8580A (en)
IL (1) IL49652A (en)
MX (1) MX3864E (en)
MY (1) MY8000275A (en)
NL (1) NL191234C (en)
NZ (1) NZ180946A (en)
SE (1) SE421426B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2127689A (en) * 1982-10-05 1984-04-18 Sandoz Ltd Calcitonin inhalation compositions
EP0246652A3 (en) * 1986-05-22 1988-02-03 Syntex (U.S.A.) Inc. Aqueous steroid formulations for nasal administration
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
WO2001007014A1 (en) * 1999-07-23 2001-02-01 Chiesi Farmaceutici S.P.A. Formulations of steroid solutions for inhalatory administration
US6413497B1 (en) 1990-02-03 2002-07-02 Boehringer Ingelheim Kg Pharmaceutical composition using a mixture of propellant gases for a metered dose inhaler
US6964759B2 (en) 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
US7018618B2 (en) 2000-05-22 2006-03-28 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7223381B2 (en) 1998-11-25 2007-05-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US7381402B2 (en) 2004-02-27 2008-06-03 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7601336B2 (en) 1997-06-13 2009-10-13 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US7696178B2 (en) 2001-07-02 2010-04-13 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US8062626B2 (en) * 1995-06-27 2011-11-22 Boehringer Ingelheim Kg Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
WO2014145067A1 (en) * 2013-03-15 2014-09-18 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
EP3124067A2 (en) * 1999-03-03 2017-02-01 Optinose AS Nasal delivery device

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH643567A5 (en) * 1979-05-21 1984-06-15 Syntex Corp METHOD FOR PRODUCING A CRYSTALLINE SHAPE OF FLUNISOLIDE.
ATE3774T1 (en) * 1980-05-02 1983-06-15 Schering Corporation BECLOMETHASONE ESTER SOLVATE, PROCESS FOR THEIR PREPARATION AND PREPARATION OF A FORMULATION.
JP2843857B2 (en) * 1988-10-05 1999-01-06 ファルマシア・アンド・アップジョン・カンパニー Finely divided solid crystalline powder via precipitation in antisolvent
DE19653969A1 (en) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg New aqueous pharmaceutical preparation for the production of propellant-free aerosols
JP5238779B2 (en) * 2003-04-25 2013-07-17 ロート製薬株式会社 Nasal drops
JP4632687B2 (en) * 2003-04-25 2011-02-16 ロート製薬株式会社 Nasal drops

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
BE585432A (en) * 1958-12-08 1960-06-08 American Cyanamid Co Fluorinated steroids.
US3282791A (en) 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3592930A (en) 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
DE2015300A1 (en) * 1969-04-01 1970-10-29 Syntex Corp., Panania;PM topical anti-inflammatory preparations and methods of their use
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
DE2332663C2 (en) 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Use of corticosteroid active ingredients for inhalation therapy
US3934013A (en) * 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2127689A (en) * 1982-10-05 1984-04-18 Sandoz Ltd Calcitonin inhalation compositions
EP0246652A3 (en) * 1986-05-22 1988-02-03 Syntex (U.S.A.) Inc. Aqueous steroid formulations for nasal administration
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US6413497B1 (en) 1990-02-03 2002-07-02 Boehringer Ingelheim Kg Pharmaceutical composition using a mixture of propellant gases for a metered dose inhaler
US8062626B2 (en) * 1995-06-27 2011-11-22 Boehringer Ingelheim Kg Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US7601336B2 (en) 1997-06-13 2009-10-13 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US8420058B2 (en) 1997-06-13 2013-04-16 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US8142763B2 (en) 1998-11-25 2012-03-27 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
US7223381B2 (en) 1998-11-25 2007-05-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US7347199B1 (en) 1998-11-25 2008-03-25 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
EP3124067A2 (en) * 1999-03-03 2017-02-01 Optinose AS Nasal delivery device
CZ299071B6 (en) * 1999-07-23 2008-04-16 Chiesi Farmaceutici S. P. A. Stable pharmaceutical steroid formulations for inhalation
US6967017B1 (en) 1999-07-23 2005-11-22 Chiesi Farmaceutici S.P.A. Formulations of steroid solutions for inhalatory administration
WO2001007014A1 (en) * 1999-07-23 2001-02-01 Chiesi Farmaceutici S.P.A. Formulations of steroid solutions for inhalatory administration
US6964759B2 (en) 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
US7018618B2 (en) 2000-05-22 2006-03-28 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7696178B2 (en) 2001-07-02 2010-04-13 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7939502B2 (en) 2001-07-02 2011-05-10 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US8168598B2 (en) 2001-07-02 2012-05-01 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7381402B2 (en) 2004-02-27 2008-06-03 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2014145067A1 (en) * 2013-03-15 2014-09-18 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
US10953021B2 (en) 2013-03-15 2021-03-23 Lupin Limited Topical compositions of flunisolide and methods of treatment

Also Published As

Publication number Publication date
AU1430176A (en) 1977-12-01
DE2624924A1 (en) 1977-12-15
FR2361900A1 (en) 1978-03-17
JPS6247880B2 (en) 1987-10-09
AT357702B (en) 1980-07-25
MY8000275A (en) 1980-12-31
SE7605927L (en) 1976-11-28
SE421426B (en) 1981-12-21
NL191234B (en) 1994-11-01
NL191234C (en) 1995-04-03
HK8580A (en) 1980-03-14
DE2661037C2 (en) 1989-04-06
NL7605699A (en) 1976-11-30
FR2361900B1 (en) 1979-04-13
JPS51144719A (en) 1976-12-13
IL49652A0 (en) 1976-07-30
MX3864E (en) 1981-08-26
CA1075228A (en) 1980-04-08
ATA388376A (en) 1979-12-15
AU506080B2 (en) 1979-12-13
NZ180946A (en) 1978-07-28
DE2624924C2 (en) 1986-11-27
ES448220A1 (en) 1977-11-01
IL49652A (en) 1979-05-31

Similar Documents

Publication Publication Date Title
GB1525181A (en) Form of flunisolide and the use of flunisolide to treat respiratory diseases
ES413911A1 (en) Chemical compounds
IE37046B1 (en) Imidazo-triazine compounds and their use in therapeutic compositions
AU1664976A (en) Removal of acid gas from process gas
ES486923A1 (en) Solutions or dispersions of polyurethanes, process for their preparation and their use.
JPS55373A (en) Medicinal compound
US1058056A (en) Caoutchouc substances and process of making same.
Friess et al. Further Observations on the Reaction of Cyclanones with Perbenzoic Acid
IE781438L (en) Tetraline derivatives
GB897332A (en) Deodorizing phosphorodithioate compounds
US3418330A (en) Novel pyridyl substituted oxetanes and derivatives thereof
IE780767L (en) Peptide complexes of desoxyribonucleic acid.
Young et al. Allylic Rearrangements. XLII. The Preparation and Some Reactions of 3β-Chlorocholest-4-ene and 3α-Chlorocholest-4-ene1
US2842570A (en) 11beta, 17beta-dihydroxy-17alpha-methylandrostane-3-ones
JPS5450488A (en) Removal of chromic acid ion from chlorate solution
US3968160A (en) Preparation of 1,2,3-tris[1,2-bis(difluoramino)ethoxy]propane
US2990415A (en) 9-substituted delta4-androstenes
ES268248A1 (en) New steroid compounds and processes for the production thereof
US4426535A (en) Method of synthesizing brevicomin and using same in beetle control
FR2453182A1 (en) Ursodesoxycholic acid for treatment of calculi - prepd. by oxidn. and redn. of chenodeoxycholic acid
Levina et al. Some derivatives of pregna-D6′-pentaranes as possible antagonists of progesterone
JPS5457478A (en) Production of aerosol product for dischaging minute fog like droplet under low temperature
GB1247606A (en) Process for the manufacture of monochloroacetyl chloride
IL60467A0 (en) Process for the removal of nitrosation agent(s)from nitrated aromatic compounds
SU623848A1 (en) Sulfoxide of 6-b-/(hexahydro-1n-azepine-1-yl)methyleneamino/-penicillanic acid as intermediate product for obtaining 7-b-/(hexahydro-1n-azepine-1-yl)methyleneamino/cephalosporanic acid or modification thereof

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
704A Declaration that licence is not available as of right for an excepted use (par. 4a/1977)
PE20 Patent expired after termination of 20 years

Effective date: 19960525